Prognostic factors in children with extragonadal malignant germ cell tumors: A pediatric intergroup study

Neyssa Marina, Wendy B. London, A. Lindsay Frazier, Stephen Lauer, Frederick Rescorla, Barbara Cushing, Marcio H. Malogolowkin, Robert P. Castleberry, Richard B. Womer, Thomas Olson

Research output: Contribution to journalArticle

56 Scopus citations

Abstract

Purpose: To investigate prognostic factors for pediatric extragonadal malignant germ cell tumors (PEMGCT). Materials and Methods: Between 1990 and 1996, patients with stage I through IV PEMGCT were eligible for a trial of cisplatin dose intensity. We retrospectively investigated prognostic factors for PEMGCT, including age, stage, primary site, treatment, and elevated alfa fetoprotein by univariate and multivariate analysis. Results: The 165 patients had a median age of 1.9 years (range, 3 days to 18.5 years); 109 were female; and 99 had alfa fetoprotein ≥ 10,000. There were 30 stage I/II, 61 stage III, and 74 stage IV tumors; primary sites included 88 sacrococcygeal, 39 thoracic, and 38 others. The 5-year overall survival (OS) and event-free survival (EFS) rates with standard deviations were 83.4% ± 3.7% and 79.0% ± 4.1%, respectively. Univariate analysis identified age ≥ 12 years as a highly significant prognostic factor for EFS (5-year EFS, 48.9% ± 15.6% v 84.1% ± 3.9%; P < .0001) and for OS (5-year OS, 53.7% ± 14.9% v 88.5% ± 3.4%; P < .0001), whereas treatment was of borderline significance (P = .0777). Multivariate Cox proportional hazards regression identified only age ≥ 12 years as a significant prognostic factor for EFS (P = .0002). In multivariate Cox regression for OS, the combination of age and primary site was highly significant (P < .0001). Patients ≥ 12 years of age with thoracic tumors had six times the risk of death compared with patients younger than 12 years with other primaries. Conclusion: Age is the most predictive factor of EFS in PEMGCT. There is a significant interaction between age and primary site, suggesting that patients ≥ 12 years of age with thoracic tumors are a biologically distinct group.

Original languageEnglish (US)
Pages (from-to)2544-2548
Number of pages5
JournalJournal of Clinical Oncology
Volume24
Issue number16
DOIs
StatePublished - Jun 1 2006
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Prognostic factors in children with extragonadal malignant germ cell tumors: A pediatric intergroup study'. Together they form a unique fingerprint.

  • Cite this

    Marina, N., London, W. B., Frazier, A. L., Lauer, S., Rescorla, F., Cushing, B., Malogolowkin, M. H., Castleberry, R. P., Womer, R. B., & Olson, T. (2006). Prognostic factors in children with extragonadal malignant germ cell tumors: A pediatric intergroup study. Journal of Clinical Oncology, 24(16), 2544-2548. https://doi.org/10.1200/JCO.2005.04.1251